Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Fulcrum Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Fulcrum Therapeutics, Inc.’s stock price such as:

• Fulcrum Therapeutics, Inc.’s current stock price and volume
• Why Fulcrum Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for FULC from analysts
• FULC’s stock price momentum as measured by its relative strength

About Fulcrum Therapeutics, Inc. (FULC)

Before we jump into Fulcrum Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Fulcrum Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Fulcrum Therapeutics, Inc..

Fulcrum Therapeutics, Inc.’s Stock Price as of Market Close

As of April 15, 2026, 3:16 PM, CST, Fulcrum Therapeutics, Inc.’s stock price was $8.190.

Fulcrum Therapeutics, Inc. is up 3.67% from its previous closing price of $7.900.

During the last market session, Fulcrum Therapeutics, Inc.’s stock traded between $7.860 and $8.230. Currently, there are approximately 65.78 million shares outstanding for Fulcrum Therapeutics, Inc..

Fulcrum Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Fulcrum Therapeutics, Inc. Stock Price History

Fulcrum Therapeutics, Inc.’s (FULC) price is currently up 6.78% so far this month.

During the month of April, Fulcrum Therapeutics, Inc.’s stock price has reached a high of $8.300 and a low of $7.300.

Over the last year, Fulcrum Therapeutics, Inc. has hit prices as high as $15.740 and as low as $2.890. Year to date, Fulcrum Therapeutics, Inc.’s stock is down 27.59%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Fulcrum Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 14, 2026, there were 0 analysts who downgraded Fulcrum Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Fulcrum Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Fulcrum Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Fulcrum Therapeutics, Inc. (FULC) by visiting AAII Stock Evaluator.

Relative Price Strength of Fulcrum Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 14, 2026, Fulcrum Therapeutics, Inc. has a weighted four-quarter relative price strength of 24.26%, which translates to a Momentum Score of 91 and is considered to be Very Strong.

Want to learn more about how Fulcrum Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Fulcrum Therapeutics, Inc. Stock Price: Bottom Line

As of April 15, 2026, Fulcrum Therapeutics, Inc.’s stock price is $8.190, which is up 3.67% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Fulcrum Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.